The European Myocardial Infarct Amiodarone Trial (EMIAT)

A. J. Camm, D. Julian, G. Janse, A. Munoz, P. Schwartz, P. Simon, G. Frangin

Research output: Contribution to journalArticlepeer-review


The objective of the European Myocardial Infarct Amiodarone Trial (EMIAT) is to assess the efficacy of amiodarone on mortality of patients with depressed left ventricular (LV) function following myocardial infarction (Ml). The rationale for the trial is as follows: patients with poor LV function after acute Ml have a high sudden cardiac death (SCD) mortality; amiodarone is a successful prophylactic therapy against SCD in patients with ventricular arrhythmias; a number of small studies (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial [CAMIAT] pilot study, Basel Antiarrhythmic Study & Infarct Survival [BASIS], and the Polish Amiodarone Trial [PAT]) of prophylactic amiodarone post AMI have shown a beneficial response attributable to amiodarone. Patients are enrolled between 5 and 21 days after acute MI if LV ejection fraction (assessed by multiplegated image acquisition nuclear angiography) is ≤40%. The study group is stratified according to ejection fraction (stratum 1,31-40%; stratum 2, 700 patients are enrolled from >60 centers (13 countries). The total study mortality (10% at 500 days) and the differential mortality of both strata are as anticipated. Side effects have been infrequent and very few patients have been withdrawn from the study. Trial conclusion is forecast for October 1995.

Original languageEnglish
JournalThe American Journal of Cardiology
Issue number16
Publication statusPublished - Nov 26 1993

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The European Myocardial Infarct Amiodarone Trial (EMIAT)'. Together they form a unique fingerprint.

Cite this